Meta-analysis of PAX1/JAM3 methylation performance in high-risk HPV-positive women.
Medicine (Baltimore)Sep 18, 2026
Lianxing Qi, Yinfang Wu, Minxia Luo
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the diagnostic performance of PAX1/JAM3 dual-gene methylation testing in high-risk HPV-positive women for detecting high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. The analysis included eight studies with 7494 participants. The pooled sensitivity for diagnosing CIN grade 2 and above was 81%, and for CIN grade 3 and above, it was 85%.
Key findings
- Pooled sensitivity for CIN grade 2 and above was 81% (95% CI: 73-88).
- Pooled specificity for CIN grade 2 and above was 95% (95% CI: 94-96).
- Pooled sensitivity for CIN grade 3 and above was 85% (95% CI: 75-92).
- Area under the curve for CIN grade 2 and above was 0.96.
Why it matters
The findings suggest that PAX1/JAM3 methylation testing could serve as an effective triage biomarker for high-risk HPV-positive women, potentially improving cervical cancer screening strategies and patient management.